Table 3.
Summary of pharmacokinetic parameter estimates for cisapride, d,l- sotalol, and moxifloxacin in conscious dogs (A) and healthy subjects (B).
| A | ||||||
|---|---|---|---|---|---|---|
| Parameter estimates | Cisapride | Sotalol | Moxifloxacin | |||
| Median | Min, Max | Mean | IIV% | Mean | IIV% | |
| AUC | ||||||
| 0.6 mg/kg | 794 | 295, 1548 | – | – | – | – |
| 2.0 mg kg−1 | 6977 | 860, 12453 | ||||
| 6.0 mg kg−1 | 6873 | 971, 17361 | ||||
| t1/2 | 4.82 | 3.57, 7.57 | – | – | – | – |
| Ka (h−1) | – | – | 1.41 | – | 1.78 | – |
| CL (l h−1) | – | – | 2.79 | 18.3 | 3.39 | 21 |
| Vc (l) | – | – | 3.15 | 100 | 43.23 | – |
| Vp (l) | – | – | 21.8 | 15.8 | – | – |
| ALAG (h) | – | – | 1.41 | – | – | – |
| Q (h−1) | – | – | 16.5 | 35.4 | – | – |
| F* | – | – | 1, 1.21 | – | – | |
| B | |||||||
|---|---|---|---|---|---|---|---|
| Parameter estimates | Cisapride* | Sotalol | Moxifloxacin | ||||
| Median | min, max | Mean | IIV% | Mean | IIV% | ||
| Ka (h−1) | – | – | 1.27 | 57.36 | 2.21 | 88.65 | |
| D1 (h−1) | – | – | – | – | 0.629 | 85.14 | |
| CL (l h−1) | 18 | 7.7, 33.1 | 9.39 | 17.15 | 13.4 | 12.69 | |
| Vss (l) | – | – | 147 | 12.73 | – | – | |
| Vc (l) | 173.5 | 17.8, 255.1 | – | – | 122 | 28.77 | |
| Vp (l) | 265.8 | 12.42, 1384 | – | – | 55.4 | 44.27 | |
| ALAG (h) | – | – | 0.45 | 38.47 | – | – | |
| Q (h−1) | 34.1 | 10.1, 395.1 | 5.58 | 0 | 78.4 | – | |
| F | 0.75 | 0.47, 1 | – | – | – | – | |
*
F estimated separately per dose level as ratio of the lowest dose
*
Values for 20 mg dose. CL, clearance; Vc, central volume of distribution; Vp, peripheral volume of distribution; Vss, volume of distribution at steady-state; Q, intercompartmental clearance; Ka, absorption rate constant; ALAG, absorption lag time; D1, duration of the putative zero order infusion into the central compartment; F, (relative) bioavailability; AUC, area under the concentration vs. time curve; t1/2, elimination half-life.